BFLY vs TAK
Butterfly Network, Inc. vs Takeda Pharmaceutical Company Limited — AI-powered side-by-side comparison
BFLY
Butterfly Network, Inc.
67
Buy
VS
TAK
Takeda Pharmaceutical Company Limited
67
Insufficient Data
| Metric | BFLY | TAK |
|---|
| AI Score |
67
|
67
|
| Price |
$9.36
|
$17.49
|
| P/E Ratio |
-32.38×
|
48.87×
|
| ROE |
-39.3%
|
2.6%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
51.1%
|
62.1%
|
| Debt / Equity |
0.10×
|
0.65×
|
| Dividend Yield |
0.0%
|
3.6%
|
| RSI (14) |
66.4
|
61.6
|
| Beta |
2.084
|
0.088
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for BFLY versus TAK.
The committee scores are tied.
BFLY and TAK both score 67/100.
BFLY Committee View
67% agreement
6 analysts
The primary driver is revenue growing 28.1% yoy -- genuine top-line momentum. The main limiting factor is roe of only -38.4% -- cheap may mean cheap for a reason. The committee is constructive but not yet at full conviction.
Bull Case
- Revenue growing 28.1% YoY -- genuine top-line momentum — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- ROE of only -38.4% -- cheap may mean cheap for a reason — Value
- Bollinger bandwidth of 52.6% signals elevated volatility — Risk
TAK Committee View
67% agreement
3 analysts
The primary driver is vix regime is low -- calm backdrop supports risk-taking. Most analysts agree, and no major concerns are blocking a stronger rating.
Bull Case
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- Price structure (LH_LL) contradicts the uptrend -- mixed signals — Technical